Why Peptide Delivery Platform Depth Is Measured in Foundational Patents Not Published Papers
Patents, not papers, show who owns a peptide delivery breakthrough.
Vikram Nandakumar
Section
4 stories in Nanomedicine Platforms.
Patents, not papers, show who owns a peptide delivery breakthrough.
Its test is whether carriers, targets, and human translation plans cohere.
Intranasal peptides reach the brain differently than IV doses.
How particle material, size, and coatings decide intranasal GLP-1 delivery.